ArticleBiosafety and health2020
Convincing the confidence to conquer COVID-19: From epidemiological intervention to laboratory investigation.
Article in Biosafety and health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.Journal of medical virology · 2024Article
- Back to Science in Searching for SARS-CoV-2 Origins.China CDC weekly · 2023Article
- Article
- Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis.Lancet (London, England) · 2023Article
- An adjusted ELISpot-based immunoassay for evaluation of SARS-CoV-2-specific T-cell responses.Biosafety and health · 2022Article
- A COVID-19 T-Cell Response Detection Method Based on a Newly Identified Human CD8China CDC weekly · 2022Article
- Immune response pattern across the asymptomatic, symptomatic and convalescent periods of COVID-19.Biochimica et biophysica acta. Proteins and proteomics · 2022Article
- A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.Frontiers in immunology · 2022Article
- A Tale of Two Cities: From Influenza HxNy to SARS-CoV-z.China CDC weekly · 2021Article
- Let's Get Vaccinated for Both Flu and COVID-19: On the World Flu Day 2021.China CDC weekly · 2021Article
- A Novel Potentially Recombinant Rodent Coronavirus with a Polybasic Cleavage Site in the Spike Protein.Journal of virology · 2021Article
- S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis.Signal transduction and targeted therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.